You are here

Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AA023707-01
Agency Tracking Number: R43AA023707
Amount: $196,305.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAAA
Solicitation Number: PA14-071
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
44 Black Bear Drive
WALTHAM, MA 02451-0249
United States
DUNS: 78278971
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SURAJ PATEL
 (908) 403-0481
 surajpatel@heprotech.com
Business Contact
 SURAJ PATEL
Phone: (908) 403-0481
Email: surajpatel@heprotech.com
Research Institution
 Stub
Abstract

? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care involves off-label administration of nonspecific corticosteroids, immunosuppressants, and antioxidants. There isa desperate need for liver-specific therapeutics that can be used to treat acute and chronic alcoholic liver disease. Heprotech was founded to commercialize therapeutics based on inhibition of gap junction communication in the liver. We have demonstratedthat liver-specific gap junctions composed of connexin 32 (Cx32) are essential to the pathogenesis of acute and chronic liver injury. We first showed that inhibitors of Cx32 gap junctions protect and rescue mice from drug-induced hepatotoxicity. Next we f

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government